Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood.2024027674
Abstract: The therapeutic success of first line quadruplet (QUAD) induction therapy and autologous stem cell transplantation (ASCT) has reinvigorated an interest in fixed-duration therapy, yet optimal short-term efficacy endpoint for treatment cessation is unknown. Using data… read more here.
Keywords: mrd; treatment cessation; response; optimal mrd ... See more keywords